A number of other equities analysts have also recently issued reports on the company. HC Wainwright cut their price target on Motus GI from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, November 15th. Piper Sandler cut their target price on Motus GI from $10.00 to $6.00 and set an “overweight” rating on the stock in a report on Monday, November 14th. Oppenheimer cut their target price on Motus GI to $5.00 in a report on Thursday, November 17th. Finally, Alliance Global Partners cut their target price on Motus GI from $12.00 to $2.25 in a report on Tuesday, November 15th.
Motus GI Stock Performance
Shares of MOTS stock opened at $1.02 on Wednesday. The stock has a market capitalization of $3.06 million, a PE ratio of -0.14 and a beta of 1.83. Motus GI has a one year low of $0.68 and a one year high of $13.00. The business’s 50 day simple moving average is $1.11 and its 200 day simple moving average is $2.43. The company has a debt-to-equity ratio of 11.98, a current ratio of 2.83 and a quick ratio of 2.65.
Hedge Funds Weigh In On Motus GI
A number of large investors have recently modified their holdings of the company. Renaissance Technologies LLC raised its position in Motus GI by 73.5% in the 2nd quarter. Renaissance Technologies LLC now owns 127,500 shares of the company’s stock valued at $36,000 after buying an additional 54,000 shares during the last quarter. Millennium Management LLC raised its position in Motus GI by 237.7% in the 2nd quarter. Millennium Management LLC now owns 114,987 shares of the company’s stock valued at $32,000 after buying an additional 80,938 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in Motus GI in the 2nd quarter valued at $56,000. 6.40% of the stock is currently owned by institutional investors.
About Motus GI
Motus GI Holdings, Inc is a medical technology company, which is dedicated to improving endoscopy outcomes and experiences. It engages in the development and commercialization of the Pure-Vu System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.
- Get a free copy of the StockNews.com research report on Motus GI (MOTS)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- Is It Time To Get Aggressive With Defense Stocks?
Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.